



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Menin-MLL inhibitor MI-2

Cat. No.:	HY-15222		
CAS No.:	1271738-62-5		
Molecular Formula:	C ₁₈ H ₂₅ N ₅ S ₂		
Molecular Weight:	375.55		
Target:	Epigenetic Reader Domain; Apoptosis		
Pathway:	Epigenetics; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (133.14 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6628 mL	13.3138 mL	26.6276 mL
		5 mM	0.5326 mL	2.6628 mL	5.3255 mL
10 mM		0.2663 mL	1.3314 mL	2.6628 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Menin-MLL inhibitor MI-2 is a Menin-MLL interaction inhibitor with IC ₅₀ of 446±28 nM.
IC₅₀ & Target	IC ₅₀ : 446±28 nM (Menin-MLL) ^[1]
In Vitro	Menin-MLL inhibitor MI-2 very effectively blocks proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI ₅₀ values of about 5 μM. Assessment of diverse hydrophobic groups at R1 led to the development of several compounds with IC ₅₀ values in the nanomolar range, including MI-2 (IC ₅₀ = 446±28 nM) and MI-3 (IC ₅₀ =648±25 nM).The dissociation constants measured

for the menin-MLL inhibitors are at the nanomolar level, $K_d=158$ nM for MI-2. MI-2 can access the protein target and very effectively inhibit the menin-MLL-AF9 interaction in human cells. Furthermore, MI-2 shows only a small effect on the cell growth of E2A-HLF transduced BMC ($GI_{50}>50$ μ M), which may be due to inhibition of the menin interaction with wild-type MLL. Treatment with MI-2 results in GI_{50} values below 10 μ M in MV4;11 (harboring MLL-AF4; $GI_{50}=9.5$ μ M), KOPN-8 (MLL-ENL; $GI_{50}=7.2$ μ M) and ML-2 (MLL-AF6; $GI_{50}=8.7$ μ M), and in MonoMac6 (MLL-AF9; $GI_{50}=18$ μ M)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay^[1]

5×10^5 HEK 293 cells/mL are plated in 12-well plates (1 mL/well) and treated with compounds (e.g., MI-2) (0.25% final concentration of DMSO for each condition) or 0.25% DMSO control and incubated for 48h at 37°C in a 5% CO₂ incubator. After incubation, 1.5×10^5 cells are harvested and resuspended in 100 μ L 1 \times Annexin V binding buffer from the Annexin V-FITC Apoptosis kit, incubated with 4 μ L of AnnexinV-FITC and 6 μ L of Propidium iodide at room temperature in the dark for 10 minutes and analyzed by flow cytometry on a LSR II instrument. Data analysis is performed using WinList software. The experiments are performed three times in triplicates with calculation of mean and standard deviation for each condition^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Syst. 2018 Apr 25;6(4):424-443.e7.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Grembecka J, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology (2012), 8(3), 277-284.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA